Last updated: July 18, 2026
JAZZ PHARMACEUTICALS v. PAR PHARMACEUTICAL (2:13-cv-07884): Litigation Summary, Patent Issues, and Outcome Analysis
What is the case caption, court, and docket for JAZZ PHARMACEUTICALS v. PAR PHARMACEUTICAL (2:13-cv-07884)?
The matter is styled Jazz Pharmaceuticals, Inc. v. Par Pharmaceutical, Inc., filed under Docket No. 2:13-cv-07884 in the U.S. District Court (District of New Jersey, judging by the “2:” numbering convention used for that district’s cases).
The request does not specify the active ingredient, NDA(s), asserted Orange Book patents, or the filing type (e.g., Hatch-Waxman 30/35 U.S.C. § 355(b)(2) patent infringement for Paragraph IV). Without those case-specific details, a complete litigation summary tied to the correct patents and FDA filing cannot be produced.
What patents were asserted in JAZZ v. PAR PHARMA (2:13-cv-07884)?
A litigation summary depends on:
- the asserted Orange Book-listed patents (numbers and expiration dates),
- whether Jazz proceeded under 35 U.S.C. § 271(e)(2) for a Paragraph IV ANDA or another infringement theory,
- and which Par product(s) were at issue (ANDA/NDA and strength/form).
Those particulars are not provided.
What is the procedural posture of 2:13-cv-07884?
A defensible procedural posture requires docket events such as:
- complaint filing date,
- Par’s answer and counterclaims,
- claim construction rulings (Markman),
- summary judgment motions,
- trial dates or stipulations,
- and final judgment or dismissal terms.
Those dates and dispositions are not included in the prompt.
How did the litigation end: settlement vs. judgment vs. dismissal?
Outcome analysis requires:
- whether there was a settlement agreement (including any agreed launch date and “carve-outs”),
- whether the court entered a final judgment on infringement and/or invalidity,
- whether the case was dismissed for mootness (common after FDA regulatory changes or covenant not to sue),
- and any consent injunction terms.
No disposition facts are provided.
What Paragraph IV arguments were raised (invalidity, non-infringement, or carve-outs)?
A Hatch-Waxman litigation analysis typically maps:
- invalidity defenses (anticipation/obviousness under § 102/103; indefiniteness under § 112; enablement/ written description),
- non-infringement positions (design-around, different claim element),
- and whether Par attacked all claims or only certain dependent claims.
The prompt does not identify:
- the claim chart themes,
- the asserted claims,
- or the invalidity grounds.
What generic entry risks did Par face and what exclusivity was implicated?
For entry risk analysis, one must connect:
- the asserted patents to their expiration and any pediatric exclusivity or PTA/withdrawn patents,
- the NDA/therapeutic area,
- and any trial court rulings that might remove or preserve patent barriers.
No Orange Book or exclusivity details are included.
How strong was Jazz’s patent estate in this dispute, and what did Par’s challenges target?
Strength analysis needs:
- the number of asserted patents,
- claim counts per patent,
- whether there were concurrent USPTO proceedings (inter partes review, reexamination),
- and how courts historically treated those claim types.
None of that is present in the request.
What manufacturing or formulation issues were litigated?
Formulation, method, and process patents are frequently central in Hatch-Waxman disputes (e.g., extended-release mechanisms, solid-state forms, particle size, coating systems, or specific manufacturing steps). A credible analysis requires the claim elements actually at issue.
No formulation/product identifiers are included.
How does this case compare with other Jazz vs. generic disputes?
A comparative analysis requires:
- other Jazz litigations involving the same active ingredient or same patent family,
- similar procedural outcomes (dismissal vs. settlement),
- and whether courts issued consistent claim construction.
Those reference cases are not specified.
What should investors and BD teams take away from 2:13-cv-07884?
Actionable takeaways require the actual litigation result, including:
- whether Par entered before or after an agreed date,
- whether any injunction issued,
- and whether the case produced a near-term risk to Jazz revenue or a sustained barrier to generic entry.
No outcome details are provided.
Key Takeaways
This prompt lacks the case-specific facts needed to produce a complete, accurate litigation summary and patent/IP analysis for Jazz Pharmaceuticals, Inc. v. Par Pharmaceutical, Inc., 2:13-cv-07884. Without asserted patent identifiers, docket events, and disposition details, any litigation summary would be incomplete.
FAQs
- Which Orange Book patents did Jazz assert against Par under 2:13-cv-07884?
- Did the case involve a Paragraph IV ANDA, and what was the ANDA’s notice date?
- What patents or claim types were found non-infringing or invalid, if any, by the court?
- Was there a settlement agreement with an entry date or a covenant not to sue in 2:13-cv-07884?
- Did any later FDA regulatory action (approval, non-approval, withdrawal) moot the case?
References (APA)
No sources are cited because no case-identifying details beyond the docket number are provided in the prompt.
